Ofatumumab. Human anti-CD20 monoclonal antibody treatment of lymphoma/leukemia treatment of rheumatoid arthritis

Drugs of the Future

Volumn 32, Issue 5, 2007, Pages 408-410

  Wang, Y ^a   Mealy, N ^b   Bayes M ^b  

^a Prous Science ^*  (United States)

^b PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CD20 ANTIBODY; CORTICOSTEROID; CYCLOPHOSPHAMIDE; FLUDARABINE; OFATUMUMAB; PLACEBO; RITUXIMAB; UNCLASSIFIED DRUG;

ANAPHYLAXIS; AREA UNDER THE CURVE; ARTICLE; B LYMPHOCYTE; BRONCHOSPASM; CANCER INHIBITION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEVER; HUMAN; HYPOTENSION; LEUKEMIA; LYMPHOMA; MAXIMUM TOLERATED DOSE; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; RHEUMATOID ARTHRITIS; RIGOR; TREATMENT FAILURE; URTICARIA;

EID: 34547799119     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2007.032.05.1100316     Document Type: Article

References (20)

1. Teeling, J., French, R.R., Cragg, M.S. et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin's lymphomas. Blood 2004, 104(6): 1793-800.
2. Teeling, J.L., van den Brakel, J., French, R. et al. Novel fully human CD20 antibodies with unusual binding activity and potent lytic activity. Clin Invest Med [12th Int Congr Immunol (July 18-23, Montreal) 2004] 2004, 27(4, Suppl.): Abst Th53.318.
3. Mackus, W., Teeling, J., van den Brakel, J. et al. In vivo characterisation of HuMax-CD20, a novel fully human antibody targeting CD20. lmmunobiology 2004, 209(4-6): Abst G. 10.
4. Mackus, W., Teeling, J., van den Brakel, J. HuMax-CD20, a novel fully human anti-CD20 monoclonal antibody: Biological properties. 11th Congr Eur Hematol Assoc (EHA) (June 15-18, Amsterdam) 2006, Abst 0619.
5. Dechant, M., Teeling, J., Beyer, T., Repp, R., Kunzendorf, U., Glennie, M.J., van de Winkel, J.G.J. Novel fully human CD20 antibodies with different mechanisms of action. Blood 2003, 102(11, Part 1): Abst 349.
6. GSK and Genmab sign worldwide agreement for HuMax-CD20. DailyDrugNews.com, December 21, 2006.
7. Genmab updates pipeline progress and future plans. DailyDrugNews.com, October 23, 2006.
8. Pivotal study begins for HuMax-CD20 in NHL. DailyDrugNews.com, July 12, 2006.
9. New phase III study evaluates HuMax-CD20 for refractory B-cell CLL. DailyDrugNews.com, May 26, 2006.
10. Hagenbeek, A., Plesner, T., Johnson, P. et al. HuMax-CD20, a novel fully human anti-CD20 monoclonal antibody: Results of a phase I/II trial in relapsed or refractory follicular non-Hodgkin's lymphoma. Blood [47th Annu Meet Am Soc Hematol (Dec 10-13, Atlanta) 2005] 2005, 106(11): Abst 4760.
11. Hagenbeek, A., Plesner, T., Johnson, P. et al. HuMax-CD20, a novel fully human anti-CD20 monoclonal antibody: Results of a phase I/II trial in relapsed or refractory follicular non-Hodgkin's lymphoma. 11th Congr Eur Hematol Assoc (EHA) (June 15-18, Amsterdam) 2006, Abst 0500.
12. Hagenbeek, A., Plesner, T., Walewski, J., Kneba, M., Petersen, J., Radford, J. A novel fully human anti-CD20 monoclonal antibody. First clinical results from an ongoing phase I/II trial in patients with follicular non-Hodgkin's lymphoma. 9th Int Conf Malig Lymphoma (June 8-11, Lugano) 2005, Abst 114.
13. Hagenbeek, A., Plesner, T., Walewski, J., Hellmann, A., Link, B.K., Dalby, L.W. HuMax-CD20 fully human monoclonal antibody in follicular lymphoma. First human exposure: Early results of an ongoing phase I/II trial. Blood 2004, 104(11, Part 1): Abst 1400.
14. Coiffier, B., Tilly, H., Pedersen, L.M. et al. Significant correlation between survival endpoints and exposure to ofatumumab (HuMax-CD20) in chronic lymphocytic leukemia. Blood [48th Annu Meet Am Soc Hematol (Dec 9-12, Orlando) 2006] 2006, 108(11): Abst 2842.
15. Coiffier, B., Tilly, H., Pedersen, L.M. et al. HuMax CD20 fully human monoclonal antibody in chronic lymphocytic leukemia. Early results from an ongoing phase I/II clinical trial. Blood [47th Annu Meet Am Soc Hematol (Dec 10-13, Atlanta) 2005] 2005, 106(11): Abst 448.
16. 1 antibody in the treatment of rheumatoid arthritis. Arthritis Rheum [70th Annu Sci Meet Am Coll Rheumatol (Nov 10-15, Washington, D.C.) 2006] 2006, 54(9, Suppl.): Abst 2122.
17. Ostergaard, M., Wiell, C., Dawes, P.T., Rigby, W., Petersen, J., Kastberg, H., Sierakowski, S. First clinical results of HuMax-CD20 fully human monoclonal IgG1 antibody treatment in rheumatoid arthritis. Annu Eur Congr Rheumatol (EULAR) (June 21-24, Amsterdam) 2006, Abst OP0018.
18. Ofatumumab with fludarabine and cyclophosphamide in B-CLL patients (NCT00410163). ClinicalTrials.gov Web site, May 20, 2007.
19. HuMax-CD20 in B-cell chronic lymphocytic leukemia (B-CLL) patients failing fludarabine and alemtuzumab (NCT00349349). ClinicalTrials.gov Web site, May 20, 2007.
20. HuMax-CD20 in follicular lymphoma (FL) patients refractory to rituximab (NCT00394836). ClinicalTrials.gov Web site, May 20, 2007.